Abstract
Abstract This article presents a preliminary and necessarily tentative and subjective assessment of the impact of new gene technology on health care costs. In the short term, diagnosis and treatment of genetic disease are likely to increase costs. Treatment with nongene therapy will continue to be far less expensive than gene therapy where it is available. Research developments to monitor as indicators of forthcoming cost reductions in genetic therapy are set forth. Some forms of genetic screening may soon reduce health care costs, and an example is provided. Genetically engineered Pharmaceuticals are described and their impact on costs reviewed. Conditions under which they are likely to reduce health care costs are indicated.
Keywords
Health careSet (abstract data type)Genetic engineeringGenetic testingBusinessMedicineHealth technologyRisk analysis (engineering)DiseaseActuarial scienceComputer scienceEconomicsEconomic growthBiologyPathologyGeneGenetics
Affiliated Institutions
Related Publications
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study
T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of h...
Musculoskeletal medicine: the challenge of the Bone and Joint Decade
Abstract The Bone and Joint Decade (2000–2010) provides a catalyst for the further development of musculoskeletal medicine. The Bone and Joint Decade (BJD) provides an opportuni...
Qualitative research methods in health technology assessment: a review of the literature.
T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact o...
Cost-Effectiveness in Health and Medicine
Abstract This is a unique, in-depth discussion of the uses and conduct of cost-effectiveness analyses (CEA) as decision-making aids in the health and medical fields. The product...
Health Care Spending in the United States and Other High-Income Countries
The United States spent approximately twice as much as other high-income countries on medical care, yet utilization rates in the United States were largely similar to those in o...
Publication Info
- Year
- 1994
- Type
- article
- Volume
- 10
- Issue
- 4
- Pages
- 546-561
- Citations
- 9
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
9
OpenAlex
Cite This
Pauline Vaillancourt Rosenau
(1994).
Reflections on the Cost Consequences of the New Gene Technology for Health Policy.
International Journal of Technology Assessment in Health Care
, 10
(4)
, 546-561.
https://doi.org/10.1017/s0266462300008151
Identifiers
- DOI
- 10.1017/s0266462300008151